Evaluation of in-vitro activity of new quinolones, macrolides, and minocycline against Mycoplasma pneumoniae

H. Ikejima; H. Yamamoto; K. Ishida; Mitsuo Kaku; J. Shimada

doi:10.1007/s101560070013

Evaluation of in-vitro activity of new quinolones, macrolides, and minocycline against Mycoplasma pneumoniae

H. Ikejima, H. Yamamoto, K. Ishida, Mitsuo Kaku, J. Shimada

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

We made a comparative study of the in-vitro activities of grepafloxacin (GPFX), ofloxacin (OFLX), erythromycin (EM), clarithromycin (CAM), roxithromycin (RXM), and minocycline (MINO) against 20 strains of Mycoplasma pneumoniae (17 clinical isolates and 3 standard strains). The minimum inhibitory concentration (MIC)90-to-minimum bactericidal concentration (MBC)90 ratio showed that the new quinolones have bactericidal effects on M. pneumoniae. Thus, it is expected that the new quinolones, especially grepafloxacin, will be clinically useful antimicrobial agents for the treatment of M. pneumoniae infection because of their good pharmacokinetic properties and bactericidal action.

Original language	English
Pages (from-to)	148-150
Number of pages	3
Journal	Journal of Infection and Chemotherapy
Volume	6
Issue number	3
DOIs	https://doi.org/10.1007/s101560070013
Publication status	Published - 2000 Jan 1
Externally published	Yes

Keywords

Grepafloxacin (GPFX)
MIC
Mycoplasma pneumoniae

ASJC Scopus subject areas

Microbiology (medical)
Pharmacology (medical)
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s101560070013

Cite this

@article{740229e08d2b454a8e2ec3e726bee90b,

title = "Evaluation of in-vitro activity of new quinolones, macrolides, and minocycline against Mycoplasma pneumoniae",

abstract = "We made a comparative study of the in-vitro activities of grepafloxacin (GPFX), ofloxacin (OFLX), erythromycin (EM), clarithromycin (CAM), roxithromycin (RXM), and minocycline (MINO) against 20 strains of Mycoplasma pneumoniae (17 clinical isolates and 3 standard strains). The minimum inhibitory concentration (MIC)90-to-minimum bactericidal concentration (MBC)90 ratio showed that the new quinolones have bactericidal effects on M. pneumoniae. Thus, it is expected that the new quinolones, especially grepafloxacin, will be clinically useful antimicrobial agents for the treatment of M. pneumoniae infection because of their good pharmacokinetic properties and bactericidal action.",

keywords = "Grepafloxacin (GPFX), MIC, Mycoplasma pneumoniae",

author = "H. Ikejima and H. Yamamoto and K. Ishida and Mitsuo Kaku and J. Shimada",

year = "2000",

month = jan,

day = "1",

doi = "10.1007/s101560070013",

language = "English",

volume = "6",

pages = "148--150",

journal = "Journal of Infection and Chemotherapy",

issn = "1341-321X",

publisher = "Elsevier BV",

number = "3",

}

TY - JOUR

T1 - Evaluation of in-vitro activity of new quinolones, macrolides, and minocycline against Mycoplasma pneumoniae

AU - Ikejima, H.

AU - Yamamoto, H.

AU - Ishida, K.

AU - Kaku, Mitsuo

AU - Shimada, J.

PY - 2000/1/1

Y1 - 2000/1/1

N2 - We made a comparative study of the in-vitro activities of grepafloxacin (GPFX), ofloxacin (OFLX), erythromycin (EM), clarithromycin (CAM), roxithromycin (RXM), and minocycline (MINO) against 20 strains of Mycoplasma pneumoniae (17 clinical isolates and 3 standard strains). The minimum inhibitory concentration (MIC)90-to-minimum bactericidal concentration (MBC)90 ratio showed that the new quinolones have bactericidal effects on M. pneumoniae. Thus, it is expected that the new quinolones, especially grepafloxacin, will be clinically useful antimicrobial agents for the treatment of M. pneumoniae infection because of their good pharmacokinetic properties and bactericidal action.

AB - We made a comparative study of the in-vitro activities of grepafloxacin (GPFX), ofloxacin (OFLX), erythromycin (EM), clarithromycin (CAM), roxithromycin (RXM), and minocycline (MINO) against 20 strains of Mycoplasma pneumoniae (17 clinical isolates and 3 standard strains). The minimum inhibitory concentration (MIC)90-to-minimum bactericidal concentration (MBC)90 ratio showed that the new quinolones have bactericidal effects on M. pneumoniae. Thus, it is expected that the new quinolones, especially grepafloxacin, will be clinically useful antimicrobial agents for the treatment of M. pneumoniae infection because of their good pharmacokinetic properties and bactericidal action.

KW - Grepafloxacin (GPFX)

KW - MIC

KW - Mycoplasma pneumoniae

UR - http://www.scopus.com/inward/record.url?scp=0033783515&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033783515&partnerID=8YFLogxK

U2 - 10.1007/s101560070013

DO - 10.1007/s101560070013

M3 - Article

C2 - 11810555

AN - SCOPUS:0033783515

VL - 6

SP - 148

EP - 150

JO - Journal of Infection and Chemotherapy

JF - Journal of Infection and Chemotherapy

SN - 1341-321X

IS - 3

ER -

Evaluation of in-vitro activity of new quinolones, macrolides, and minocycline against Mycoplasma pneumoniae

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this